ATE521629T1 - Matrixmetalloproteinase-11-impfstoff - Google Patents
Matrixmetalloproteinase-11-impfstoffInfo
- Publication number
- ATE521629T1 ATE521629T1 AT06792355T AT06792355T ATE521629T1 AT E521629 T1 ATE521629 T1 AT E521629T1 AT 06792355 T AT06792355 T AT 06792355T AT 06792355 T AT06792355 T AT 06792355T AT E521629 T1 ATE521629 T1 AT E521629T1
- Authority
- AT
- Austria
- Prior art keywords
- mmp
- compositions
- terminus
- linked
- immunoenhancing element
- Prior art date
Links
- 108010076502 Matrix Metalloproteinase 11 Proteins 0.000 title abstract 10
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 102000011723 Matrix Metalloproteinase 11 Human genes 0.000 title 1
- 102100028847 Stromelysin-3 Human genes 0.000 abstract 7
- 239000000203 mixture Substances 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 230000002766 immunoenhancing effect Effects 0.000 abstract 3
- 102000017303 Stromelysin-3 Human genes 0.000 abstract 2
- 230000004927 fusion Effects 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108020004705 Codon Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 238000011443 conventional therapy Methods 0.000 abstract 1
- 210000005260 human cell Anatomy 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
- C12N9/6416—Metalloendopeptidases (3.4.24)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72449805P | 2005-10-07 | 2005-10-07 | |
| PCT/EP2006/009536 WO2007042169A2 (en) | 2005-10-07 | 2006-10-03 | Matrix metalloproteinase 11 vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE521629T1 true ATE521629T1 (de) | 2011-09-15 |
Family
ID=37451271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06792355T ATE521629T1 (de) | 2005-10-07 | 2006-10-03 | Matrixmetalloproteinase-11-impfstoff |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8106176B2 (https=) |
| EP (1) | EP1934246B8 (https=) |
| JP (1) | JP5361386B2 (https=) |
| CN (1) | CN101365715B (https=) |
| AT (1) | ATE521629T1 (https=) |
| AU (1) | AU2006301582B2 (https=) |
| CA (1) | CA2623531C (https=) |
| ES (1) | ES2370040T3 (https=) |
| WO (1) | WO2007042169A2 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| TW201803586A (zh) | 2008-08-14 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 使用ｇｄｆ阱以增加紅血球水平 |
| EP2568044B1 (en) * | 2008-09-29 | 2015-04-08 | The Trustees of The University of Pennsylvania | Tumor vascular marker-targeted vaccines |
| KR20120049214A (ko) | 2009-06-08 | 2012-05-16 | 악셀레론 파마 인코포레이티드 | 발열성 지방세포를 증가시키는 방법 |
| AU2010282361B2 (en) * | 2009-08-13 | 2015-03-19 | Acceleron Pharma Inc. | Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels |
| CN107028886A (zh) | 2009-11-04 | 2017-08-11 | 不列颠哥伦比亚大学 | 含有核酸的脂质粒子及相关的方法 |
| WO2013059922A1 (en) | 2011-10-25 | 2013-05-02 | The University Of British Columbia | Limit size lipid nanoparticles and related methods |
| CN105143456A (zh) | 2013-03-15 | 2015-12-09 | 不列颠哥伦比亚大学 | 用于转染的脂质纳米粒子和相关方法 |
| LT3388075T (lt) | 2015-03-27 | 2023-11-10 | Immatics Biotechnologies Gmbh | Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš įvairius navikus (seq id 25 - mrax5-003) |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| CN110418648B (zh) * | 2017-02-22 | 2023-09-08 | 丁恩雨 | 一种编码人GM-CSF与多串连表位融合的mRNA癌症疫苗 |
| US20220362402A1 (en) * | 2019-10-08 | 2022-11-17 | Exhaura, Ltd. | Compositions and methods for ocular therapy |
| US20240199725A1 (en) | 2021-04-16 | 2024-06-20 | Korea University Research And Business Foundation | Human antibody targeting covid-19 virus |
| GB202117583D0 (en) * | 2021-12-06 | 2022-01-19 | Cambridge Entpr Ltd | Protein expression |
| CN116590263A (zh) * | 2023-07-02 | 2023-08-15 | 广州庆毅生物医药科技有限公司 | 一种重组蛋白、单克隆抗体及其检测试剂盒和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL78775A (en) * | 1985-05-15 | 1992-06-21 | Biotech Australia Pty Ltd | Oral vaccines |
| GB9112553D0 (en) | 1991-06-11 | 1991-07-31 | Wellcome Found | Fusion proteins |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| NZ332954A (en) * | 1996-05-23 | 2000-07-28 | Xoma Corp | Use of BPI protein products to treat humans with hemorrhage due to trauma |
| US6114148C1 (en) * | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| BR0010077A (pt) | 1999-04-26 | 2002-01-15 | K U Leuven Res & Dev Universit | Gene sintético para expressão de uma proteìna retroviral ativa em eucariotas |
| CA2385172A1 (en) * | 1999-10-08 | 2001-04-19 | Active Biotech Ab | Ab5 toxin b subunit mutants with altered chemical conjugation characteristics |
| GB9930768D0 (en) * | 1999-12-29 | 2000-02-16 | Pfizer Ltd | Composition |
| JP2004508064A (ja) | 2000-09-15 | 2004-03-18 | メルク エンド カムパニー インコーポレーテッド | コドン最適化ｈｉｖ１−ｇａｇ、ｐｏｌ、ｎｅｆおよび修飾体を発現する増強された第１世代アデノウイルスワクチン |
| US20040110152A1 (en) | 2002-12-10 | 2004-06-10 | Isis Pharmaceuticals Inc. | Modulation of matrix metalloproteinase 11 expression |
| GB0321615D0 (en) * | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
| EA012066B1 (ru) * | 2003-10-10 | 2009-08-28 | Паудерджект Вэксинс, Инк. | Способ, вызывающий т-клеточный ответ |
| CA2555013C (en) * | 2004-02-11 | 2013-10-15 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Carcinoembryonic antigen fusions and uses thereof |
-
2006
- 2006-10-03 CA CA2623531A patent/CA2623531C/en not_active Expired - Fee Related
- 2006-10-03 JP JP2008533917A patent/JP5361386B2/ja not_active Expired - Fee Related
- 2006-10-03 AT AT06792355T patent/ATE521629T1/de not_active IP Right Cessation
- 2006-10-03 US US12/083,031 patent/US8106176B2/en active Active
- 2006-10-03 ES ES06792355T patent/ES2370040T3/es active Active
- 2006-10-03 CN CN2006800370642A patent/CN101365715B/zh not_active Expired - Fee Related
- 2006-10-03 AU AU2006301582A patent/AU2006301582B2/en not_active Ceased
- 2006-10-03 WO PCT/EP2006/009536 patent/WO2007042169A2/en not_active Ceased
- 2006-10-03 EP EP06792355A patent/EP1934246B8/en active Active
-
2011
- 2011-12-21 US US13/332,580 patent/US8492522B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2370040T3 (es) | 2011-12-12 |
| EP1934246A2 (en) | 2008-06-25 |
| JP5361386B2 (ja) | 2013-12-04 |
| CN101365715B (zh) | 2013-03-27 |
| AU2006301582B2 (en) | 2011-10-13 |
| WO2007042169A3 (en) | 2007-05-31 |
| US8106176B2 (en) | 2012-01-31 |
| US20120177679A1 (en) | 2012-07-12 |
| US8492522B2 (en) | 2013-07-23 |
| CA2623531C (en) | 2013-12-10 |
| CA2623531A1 (en) | 2007-04-19 |
| JP2009509553A (ja) | 2009-03-12 |
| CN101365715A (zh) | 2009-02-11 |
| EP1934246B8 (en) | 2012-02-08 |
| US20090155298A1 (en) | 2009-06-18 |
| EP1934246B1 (en) | 2011-08-24 |
| WO2007042169A2 (en) | 2007-04-19 |
| AU2006301582A1 (en) | 2007-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE521629T1 (de) | Matrixmetalloproteinase-11-impfstoff | |
| PH12023550266A1 (en) | Anti-ceacam5 antibodies and conjugates and uses thereof | |
| BR0113491A (pt) | Polinucleotìdeo e polipeptìdeo isolados, vetor de expressão, célula hospedeira, proteìna de fusão, métodos para estimular e/ou expandir células t especìficas para uma protéina de tumor, para estimular uma resposta imune em um paciente, para o tratamento de um câncer em um paciente e para inibir o desenvolvimento de um câncer em um paciente, população de célula t isolada, composição, e, uso de um componente. | |
| HUP0302532A2 (hu) | Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások | |
| DK1549353T3 (da) | Anvendelse af alfa(1,3)galactosyltransferaseudtrykkende allogene tumorceller til vaccination mod tumorer | |
| PT1200590E (pt) | Antigénio transmembranar lectina tipo c expresso em cancro da próstata humano e utilizações do mesmo | |
| BRPI0509201A (pt) | agentes de acoplamento de receptor e usos terapêuticos destes | |
| TR200103560T2 (tr) | Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı | |
| BR112012023621A2 (pt) | composição dos peptídeos associados a tumor e vacina anticâncer relacionada para o tratamento do câncer gástrico e outros cânceres | |
| TW200719910A (en) | C. perfringens alpha toxoid vaccine | |
| DE602006019446D1 (de) | An humane leukozytenantigen-(hla-)klasse-i- oder ii-moleküle bindende tumorassoziierte peptide und damit im zusammenhang stehender impfstoff gegen krebs | |
| DK1806359T3 (da) | Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler | |
| WO2002089747A3 (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
| TR200003879T2 (tr) | İn vivo ışın tedavisine duyarlılaştırıcı özelliklere sahip farnesil protein transferaz inhibitörleri@ | |
| WO2001051633A3 (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
| WO2001072295A3 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
| WO2001073032A3 (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
| EA200970607A1 (ru) | Универсальная вакцина из опухолевых клеток для противораковой терапии и профилактического использования | |
| BR112019007210A2 (pt) | métodos e composições para o tratamento da doença de fabry | |
| AR031250A1 (es) | Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon | |
| BR112021025699A2 (pt) | Anticorpos anti-mesotelina e imunoconjugados dos mesmos | |
| CL2022001727A1 (es) | Anticuerpos específicos contra la claudina 18.2 tumoral | |
| ES2187568T3 (es) | Vacuna viva para el tratamiento de enfermedades tumorales. | |
| PH12022551078A1 (en) | Combination therapy to treat brain cancer | |
| MX2009003679A (es) | Composicion de adn para provocar una respuesta inmune contra los macrofagos asociados a tumores. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |